Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Savara Inc. due to alleged violations of federal securities laws related to misleading statements about the company's Biologics License Application (BLA) for MOLBREEVI, which has led to significant investor losses [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Savara between March 7, 2024, and May 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Savara, with a deadline of November 7, 2025, for investors to seek the role of lead plaintiff [4][8]. - The complaint alleges that Savara and its executives made false and misleading statements regarding the MOLBREEVI BLA, impacting investor decisions [6]. Group 2: Financial Impact - Following the announcement of a refusal to file letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90 per share, or 31.69%, closing at $1.94 per share on May 27, 2025 [7]. - The allegations suggest that the delay in regulatory approval for MOLBREEVI may necessitate Savara to raise additional capital, further impacting its financial stability [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [5]. - The firm is actively seeking information from whistleblowers, former employees, and shareholders regarding Savara's conduct [9].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 7, 2025 deadline [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, and that the public statements made by the defendants were materially false and misleading [4]

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until November 7, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? On May ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Points - A class action lawsuit has been filed against Savara Inc. for failing to disclose critical information regarding the MOLBREEVI Biologics License Application (BLA) during the class period from March 7, 2024, to May 23, 2025 [2][8] - The lawsuit claims that the FDA was unlikely to approve the MOLBREEVI BLA in its current form due to insufficient information, which could lead to delays in regulatory approval and the need for Savara to raise additional capital [8] Allegation Details - The complaint alleges that Savara did not disclose that the MOLBREEVI BLA lacked sufficient information regarding its chemistry, manufacturing, and controls [8] - On May 27, 2025, Savara announced it received a refusal to file (RTF) letter from the FDA, causing its stock price to drop by $0.90, or 31.69%, closing at $1.94 per share [8] Next Steps - Investors who purchased Savara shares and suffered losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 7, 2025 [2] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5] - The firm has offices in New York, California, and South Carolina, and provides services in commercial and securities litigation [5]

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=170628&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The c ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruq ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Savara To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading nationa ...

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly, the FDA was unlikely to approve the MOLBREEVI BLA in its current form; (3) the foregoing made it unlikely that Savara would complete submission of the MO ...

Accessibility StatementSkip Navigation The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by th ...